BDF Gestion Makes New $1.96 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

BDF Gestion bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, Holdings Channel reports. The institutional investor bought 5,033 shares of the biopharmaceutical company’s stock, valued at approximately $1,956,000.

A number of other large investors have also recently bought and sold shares of the business. Dakota Wealth Management raised its holdings in shares of Regeneron Pharmaceuticals by 2.9% during the fourth quarter. Dakota Wealth Management now owns 1,366 shares of the biopharmaceutical company’s stock valued at $973,000 after buying an additional 39 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 64.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 48,856 shares of the biopharmaceutical company’s stock valued at $34,802,000 after buying an additional 19,114 shares during the last quarter. Traphagen Investment Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 51.2% during the fourth quarter. Traphagen Investment Advisors LLC now owns 688 shares of the biopharmaceutical company’s stock valued at $490,000 after buying an additional 233 shares during the last quarter. Sheets Smith Wealth Management raised its holdings in shares of Regeneron Pharmaceuticals by 4.0% during the fourth quarter. Sheets Smith Wealth Management now owns 1,160 shares of the biopharmaceutical company’s stock valued at $826,000 after buying an additional 45 shares during the last quarter. Finally, Enclave Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 31.5% during the fourth quarter. Enclave Advisors LLC now owns 392 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 94 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.1 %

NASDAQ REGN opened at $680.03 on Thursday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a market cap of $74.73 billion, a price-to-earnings ratio of 16.83, a PEG ratio of 1.62 and a beta of 0.10. The firm’s 50 day moving average price is $733.06 and its two-hundred day moving average price is $943.95.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on REGN. Piper Sandler cut their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Morgan Stanley cut their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Wells Fargo & Company lowered their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Sanford C. Bernstein lowered their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Finally, Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.